Lisa-Marie Niestroj

Lisa-Marie Niestroj

Auto-generated profile, based on publicly available information

Lisa-Marie Niestroj

Cologne Center for Genomics, University of Cologne, Cologne, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Cell
Verified
Journal Article
Closed access
RCRyan L. Collins
Ryan L. Collins
JGJoseph Glessner
Joseph Glessner
EPEleonora Porcu
Eleonora Porcu
MLMaarja Lepamets
Maarja Lepamets
RBRhonda Brandon
Rhonda Brandon
MTMichael E. Talkowski
Michael E. Talkowski

16 July 2019 in Epilepsia
Verified
Journal Article
Closed access
PDF file
SDScott T. Demarest
Scott T. Demarest
HOHeather E. Olson
Heather E. Olson
AMAngela Moss
Angela Moss
EPElia Pestana‐Knight
Elia Pestana‐Knight
XZXiaoming Zhang
Xiaoming Zhang
TBTim A. Benke
Tim A. Benke

1 July 2020 in Brain
Verified
Journal Article
Open access
PDF file
LNLisa-Marie Niestroj
Lisa-Marie Niestroj
EPEduardo Perez-Palma
Eduardo Perez-Palma
DHDaniel P Howrigan
Daniel P Howrigan
YZYadi Zhou
Yadi Zhou
FCFeixiong Cheng
Feixiong Cheng
DLDennis Lal
Dennis Lal
Cytogenic testing is routinely applied in most neurological centres for severe paediatric epilepsies. However, which characteristics of copy number variants (CNVs) confer most epilepsy risk and which epilepsy subtypes carry the most CNV burden, have not been explored on a genome-wide scale. Here, we present the largest CNV investigation in epilepsy to date with 10 712 European epilepsy cases and 6746 ancestry-matched controls. Patients with genetic generalized epilepsy, lesional focal epilepsy, non-acquired focal epilepsy, and developmental and epileptic encephalopathy were included. All samples were processed with the same technology and analysis pipeline. All investigated epilepsy types, including lesional focal epilepsy patients, showed an increase in CNV burden in at least one tested category compared to controls. However, we observed striking differences in CNV burden across epilepsy types and investigated CNV categories. Genetic generalized epilepsy patients have the highest CNV burden in all categories tested, followed by developmental and epileptic encephalopathy patients. Both epilepsy types also show association for deletions covering genes intolerant for truncating variants. Genome-wide CNV breakpoint association showed not only significant loci for genetic generalized and developmental and epileptic encephalopathy patients but also for lesional focal epilepsy patients. With a 34-fold risk for developing genetic generalized epilepsy, we show for the first time that the established epilepsy-associated 15q13.3 deletion represents the strongest risk CNV for genetic generalized epilepsy across the whole genome. Using the human interactome, we examined the largest connected component of the genes overlapped by CNVs in the four epilepsy types. We observed that genetic generalized epilepsy and non-acquired focal epilepsy formed disease modules. In summary, we show that in all common epilepsy types, 1.5–3% of patients carry epilepsy-associated CNVs. The characteristics of risk CNVs vary tremendously across and within epilepsy types. Thus, we advocate genome-wide genomic testing to identify all disease-associated types of CNVs.

24 September 2019 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
ZMZohreh Mehrjoo
Zohreh Mehrjoo
ZFZohreh Fattahi
Zohreh Fattahi
MBMaryam Beheshtian
Maryam Beheshtian
MMMarzieh Mohseni
Marzieh Mohseni
HPHossein Poustchi
Hossein Poustchi
MNMichael Nothnagel
Michael Nothnagel
Iran, despite its size, geographic location and past cultural influence, has largely been a blind spot for human population genetic studies. With only sparse genetic information on the Iranian population available, we pursued its genome-wide and geographic characterization based on 1021 samples from eleven ethnic groups. We show that Iranians, while close to neighboring populations, present distinct genetic variation consistent with long-standing genetic continuity, harbor high heterogeneity and different levels of consanguinity, fall apart into a cluster of similar groups and several admixed ones and have experienced numerous language adoption events in the past. Our findings render Iran an important source for human genetic variation in Western and Central Asia, will guide adequate study sampling and assist the interpretation of putative disease-implicated genetic variation. Given Iran’s internal genetic heterogeneity, future studies will have to consider ethnic affiliations and possible admixture. Based on genome-wide genotype data on over 1000 samples from eleven ethnic groups present in Iran and by comparison to reference data sets of both extant populations and ancient DNA samples, we show that the Iranian population comprises distinct genetic variation with respect to populations in close geographic proximity, a cluster of genetically largely overlapping ethnic groups as well as a number of strongly admixed groups. These observations, also corroborated by f3 migration statistics and other approaches, indicate genetic continuity of and limited influx into the cluster groups over several millennia, despite Iran’s geographic position at a crossroads in West Asia. They also suggest, correspondingly, several instances of language adoption instead of demic replacement in the past. Future human genetic studies, both with a focus on population and medical genetics, will have to consider differences in heterogeneity, consanguinity and degree of admixture between the ethnic groups for an adequate design and interpretation.

3 January 2020 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
LYLamis Yehia
Lamis Yehia
MSMarilyn Seyfi
Marilyn Seyfi
LNLisa-Marie Niestroj
Lisa-Marie Niestroj
RPRoshan Padmanabhan
Roshan Padmanabhan
YNYing Ni
Ying Ni
CECharis Eng
Charis Eng
The triumph of using genetics in precision medicine is the ability to stratify individuals at very high risk of disease and thereby enact specific gene-informed medical management.1,2 In the case of heritable disease, genetics also allow testing of family members to determine with 100% accuracy whether they are at risk of disease. However, for any single individual carrying a mutation, we can estimate risk by probabilities but not with certainty. For example, a germline mutation in gene X may give an 80% lifetime risk of disease Y, but for the single patient with that germline mutation, the risk of developing disease Y will be 100% or 0%. Searching for genomic modifiers of heritable disease risk at the individual level in humans has proven challenging.1,3 This makes estimation of clinical outcomes difficult, especially for phenotypically variable disorders. As such, why a mutation in 1 particular gene predisposes to disparate clinical outcomes, including in patients with identical mutations, remains poorly understood.

29 July 2019 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
LNLisa-Marie Niestroj
Lisa-Marie Niestroj
Patrick MayPatrick May
Patrick May
MAMykyta Artomov
Mykyta Artomov
KKKatja Kobow
Katja Kobow
RCRoland Coras
Roland Coras
DLDennis Lal
Dennis Lal